Flores Vanessa da Costa, Siqueira Fallon Dos Santos, Mizdal Caren Rigon, Bonez Pauline Cordenonsi, Agertt Vanessa Albertina, Stefanello Sílvio Terra, Rossi Grazielle Guidolin, Campos Marli Matiko Anraku de
Programa de Pós-graduação em Ciências Farmacêuticas, Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Brazil.
Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Departamento de Química, Universidade Federal de Santa Maria, Brazil.
Microb Pathog. 2016 Oct;99:229-235. doi: 10.1016/j.micpath.2016.08.017. Epub 2016 Aug 20.
Rapidly growing mycobacteria (RGM) are opportunistic pathogens found in the environment. When in biofilms, mycobacteria is highly resistant to antibacterial treatments. The purpose of this study is to evaluate the antibiofilm activity of antimicrobials commonly used in therapy against mycobacteria. The antimicrobial susceptibility of Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium massiliense was determined in planktonic and sessile populations. The antimicrobials amikacin, ciprofloxacin, clarithromycin, doxycycline, imipenem and sulfamethoxazole were tested. For each drug, it was evaluated the susceptibility of the pathogen, the ability to inhibit biofilm formation and the resistance of biofilms to antimicrobial activity. Results showed although, the antimicrobials tested are used as an alternative therapy for RGM, M. abscessus proved to be resistant to clarithromycin, beside that, M. massiliense showed a resistant profile to clarithromycin and sulfamethoxazole. Moreover, the inhibition of biofilm formation and its destruction have not been fully met. Considering that the biofilms are a known form of bacterial resistance, the failure of alternatives to inhibit or destroy biofilms can trigger the recurrence of infections. In RGM, besides causing treatment failures, biofilms are a factor of pathogenic risk, since these microorganisms are found in environmental sources and can cause infections easily.
快速生长分枝杆菌（RGM）是在环境中发现的机会性病原体。当处于生物膜中时，分枝杆菌对抗菌治疗具有高度抗性。本研究的目的是评估治疗分枝杆菌常用抗菌药物的抗生物膜活性。在浮游菌和固着菌群体中测定了脓肿分枝杆菌、偶发分枝杆菌和马赛分枝杆菌的抗菌药敏性。测试了阿米卡星、环丙沙星、克拉霉素、强力霉素、亚胺培南和磺胺甲恶唑等抗菌药物。对于每种药物，评估了病原体的药敏性、抑制生物膜形成的能力以及生物膜对抗菌活性的抗性。结果显示，尽管所测试的抗菌药物被用作RGM的替代疗法，但脓肿分枝杆菌被证明对克拉霉素耐药，此外，马赛分枝杆菌对克拉霉素和磺胺甲恶唑呈现耐药性。此外，生物膜形成的抑制及其破坏尚未完全实现。鉴于生物膜是一种已知的细菌耐药形式，替代药物无法抑制或破坏生物膜可能会引发感染复发。在RGM中，生物膜除了导致治疗失败外，还是致病风险因素，因为这些微生物存在于环境源中，容易引发感染。
